✦ LIBER ✦

Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. phenotypic and functional analysis of the peripheral blood mononuclear cells

✍ Scribed by Claudio Fortis; Elisabetta Ferrero; Carlo Besana; Mauro Biffi; Silvia Heltai; Laura Galli; Anna Borri; Alisa Schoenheit; Claudio Rugarli

Publisher: Springer-Verlag
Year: 1990
Tongue: English
Weight: 735 KB
Volume: 32
Category: Article
ISSN: 0340-7004
DOI: 10.1007/bf01771451

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The augmentation of lymphokine-activated

The augmentation of lymphokine-activated killer activity following pulsing of human peripheral blood mononuclear cells with recombinant human interleukin-2

✍ C. R. D. Carter; B. W. Hancock; R. C. Rees 📂 Article 📅 1992 🏛 Springer-Verlag 🌐 English ⚖ 925 KB

Cytotoxic cell function and phenotypic a

Cytotoxic cell function and phenotypic analysis of peripheral blood mononuclear cells in cancer patients treated with low-dose interleukin-2 and mitomycin C

✍ Shinya Arinaga; Nobuya Karimine; Masashi Adachi; Hiroshi Inoue; Shigeru Nanbara; 📂 Article 📅 1993 🏛 Springer-Verlag 🌐 English ⚖ 758 KB

Recombinant interleukin-2 and lymphokine

Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation

✍ Claudio Fortis; Elisabetta Ferrero; Mauro Biffi; Silvia Heltai; Carlo Besana; Er 📂 Article 📅 1991 🏛 Springer-Verlag 🌐 English ⚖ 689 KB

Lack of correlation between peripheral b

Lack of correlation between peripheral blood lymphokine-activated killer (lak) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2

✍ A. K. Ghosh; H. Dazzi; N. Thatcher; M. Moore 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 634 KB

A phase-1/11 study of recombinant interleukin 2 (rll-2) was performed in 31 melanoma patients. The first dose of rlL-2 was given intrasplenically followed 4 hr later by an i.v. dose and 3 further i.v. doses on alternate days. Three courses of treatment were planned at 3-week intervals. The maximum t

Comparison of suppressor and cytotoxic a

Comparison of suppressor and cytotoxic activity of blood mononuclears during adaptive immunotherapy of cancer patients with lymphokine-activated killer cells with a low dose of recombinant interleukin-2

✍ I. F. Abronina; T. A. Kupriyanova; A. V. Bolvachova; S. N. Bykovskaya; O. M. Dro 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 345 KB

Lymphokine-activated killer cell activit

Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients

✍ Nobuya Karimine; Shigeru Nanbara; Shinya Arinaga; Tsukasa Asoh; Hiroaki Ueo; Tsu 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 661 KB

Lymphokine-activated killer (LAK) cell activity of peripheral blood mononuclear cells (PBM), spleen cells (SPC), regional lymph node cells (LNC), and tumor-infiltrating lymphocytes (TIL), induced by activation with interleukin 2 (IL 2) for 4 days, was evaluated in patients with gastric carcinoma. TI